Publications by authors named "Michael A O'Donnell"

Claim this Profile
P
Presence of an Artificial Intelligence-powered Predictive Biomarker Is Associated with a Poor Response to Intravesical Bacillus Calmette-Guerin but Not to Intravesical Sequential Gemcitabine/Docetaxel in Patients with High-grade Non-muscle-invasive Bladder Cancer.
Vignesh T Packiam, Ian M McElree, Saum Ghodoussipour, Vivek Nimgaonkar, Viswesh Krishna, Michael A O'Donnell

Eur Urol Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intermediate-risk Non-muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification, Management Strategies, and Clinical Trial Design from the International Bladder Cancer Group.
Roger Li, Patrick J Hensley, Marko Babjuk, Laura Bukavina, Sarah P Psutka, Michael A O'Donnell

Eur Urol Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended Outcomes of Intravesical Valrubicin and Docetaxel as a Secondary Salvage Treatment for Recalcitrant High-risk Non-muscle-invasive Bladder Cancer.
Ian M McElree, Ryan L Steinberg, Helen Y Hougen, Sarah L Mott, Vignesh T Packiam, Michael A O'Donnell

Eur Urol Focus· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Male reproductive and sexual health outcomes following intravesical therapy for non-muscle invasive bladder cancer.
Mohamad Abou Chakra, Igor Duquesne, Mahmoud Mima, Samuel Ohlander, Adam J Kemp, Michael A O'Donnell

World J Urol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug-releasing intravesical floating technology for sequential gemcitabine and docetaxel in non-muscle-invasive bladder cancer.
Ashley C Rhodes, Kaitlyn A McClintic, Emily Witt, Ikenna Nwosu, Kyle R Balk, Michael A O'Donnell

BJU Int· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Global insights into the management of BCG-unresponsive non-muscle invasive bladder cancer: a narrative review of provider surveys.
Mohamad Abou Chakra, Igor Duquesne, Mahmoud Mima, Mohamad Moussa, Michael A O'Donnell

Transl Androl Urol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Computational Histology Artificial Intelligence (CHAI) Enhances Risk Stratification of High-grade Ta Non-muscle-invasive Bladder Cancer in a Multicenter Cohort: Comparison to Current European Association of Urology and American Urological Association Stratification Schemes.
Sam S Chang, Bryn Launer, Vikram Narayan, Dattatraya Patil, Michael A O'Donnell

Eur Urol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcomes of a cascading salvage strategy for high-risk non-muscle-invasive bladder cancer.
Ian M McElree, Ryan L Steinberg, Helen Y Hougen, Sarah L Mott, Vignesh T Packiam, Michael A O'Donnell

BJU Int· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bladder-sparing management for high grade noninvasive urothelial carcinoma of the prostate.
Alexander C Martin, Ian M McElree, Sarah L Mott, Helen Y Hougen, Ryan L Steinberg, Michael A O'Donnell

Urol Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the efficacy and safety of sequential intravesical gemcitabine and docetaxel - does time from transurethral resection of bladder tumour to induction matter?
Ian M McElree, Grant M Henning, Ryan L Steinberg, Helen Y Hougen, Sarah L Mott, Michael A O'Donnell

BJU Int· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy of sequential intravesical gemcitabine and docetaxel versus BCG for the treatment of European association of urology very-high risk non-muscle invasive bladder cancer.
Mohamad Abou Chakra, Vignesh T Packiam, Ian M McElree, Sarah L Mott, Michael A O'Donnell

Urol Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Tumor Stage on Oncologic Outcomes of High-grade Bacillus Calmette-Guérin Unresponsive Non-muscle-invasive Bladder Cancer Undergoing Bladder-sparing Therapies.
Drupad Annapureddy, Jacob I Taylor, Ashish M Kamat, Michael A O'Donnell, Jeffrey Howard

Eur Urol Focus· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of blue light cystoscopy and additional operative evaluations during first surveillance after induction therapy for high-risk NMIBC.
Ian M McElree, Ryan L Steinberg, Sarah L Mott, Helen Y Hougen, Michael A O'Donnell

Bladder Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Guérin in Patients with Bacillus Calmette-Guérin-Unresponsive Non-Muscle Invasive Bladder Cancer.
Jacob Taylor, Ashish M Kamat, Drupad Annapureddy, Zine-Eddine Khene, Jeffrey Howard, Michael A O'Donnell

Eur Urol Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Desmocollin-3 and Bladder Cancer.
Chandreshwar P Shukla, Nayan K Jain, Michael A O'Donnell, Kapil V Vachhani, Rashmi Patel

Diseases· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancer.
Jacob I Taylor, Ashish M Kamat, Michael A O'Donnell, Drupad Annapureddy, Jeffrey Howard

BJU Int· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting Response to Intravesical Bacillus Calmette-Guérin in High-Risk Nonmuscle-Invasive Bladder Cancer Using an Artificial Intelligence-Powered Pathology Assay: Development and Validation in an International 12-Center Cohort.
Yair Lotan, Viswesh Krishna, Waleed M Abuzeid, Bryn Launer, Sam S Chang, Michael A O'Donnell

J Urol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic role of the neutrophil/lymphocyte ratio in high-risk BCG-naïve non-muscle-invasive bladder cancer treated with intravesical gemcitabine/docetaxel.
Mohamad Abou Chakra, Riitta Lassila, Nancy El Beayni, Sarah L Mott, Michael A O'Donnell

BJU Int· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Saudi urologists' treatment pattern for high-risk Calmette-Guérin naïve and Calmette-Guérin unresponsive nonmuscle invasive bladder cancer.
Mohammad Alghafees, Mohamad Abou Chakra, Abdullah Alkhayal, Mohamad Moussa, Mohammad Alkhamees, Michael A O'Donnell

Urol Ann· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential Endoluminal Doxorubicin and Gemcitabine Alternating Weekly with Sequential Mitomycin and Docetaxel for Recurrent Non-Muscle Invasive Urothelial Carcinoma.
Ian M McElree, Vignesh T Packiam, Ryan L Steinberg, Helen Y Hougen, Mohamad Abou Chakra, Michael A O'Donnell

Cancers (Basel)· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Multinational, Multi-Institutional Study Assessing the Impact of Diabetes Mellitus on the Prognosis of Patients with Non-Muscle Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin.
Mohamad Abou Chakra, Igor Duquesne, Michael Peyromaure, Sarah L Mott, Mohamad Moussa, Michael A O'Donnell

Nutr Cancer· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Update on the Mechanism of Action of Intravesical BCG Therapy to Treat Non-Muscle-Invasive Bladder Cancer.
Mohamad Abou Chakra, Yi Luo, Igor Duquesne, Michael A O'Donnell

Front Biosci (Landmark Ed)· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Establishing an Intravesical Doublet Chemotherapy Clinic for Nonmuscle-Invasive Bladder Cancer Patients.
Mohamad Abou Chakra, Neal D Shore, Erica S Brown, Guixin J Du, Michael A O'Donnell

Urol Pract· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential Endoluminal Gemcitabine and Cabazitaxel with Intravenous Pembrolizumab as a Bladder-Preserving Strategy for Docetaxel-Unresponsive Non-Muscle Invasive Urothelial Carcinoma Following Transurethral Resection of Bladder Tumor.
Ian M McElree, Vignesh T Packiam, Ryan L Steinberg, Helen Y Hougen, Sarah L Mott, Michael A O'Donnell

Cancers (Basel)· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer.
Elaine Chang, Noah M Hahn, Seth P Lerner, Jaleh Fallah, Sundeep Agrawal, Michael A O'Donnell

Bladder Cancer· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis